A Study in Healthy Japanese Young Adults to Assess the Safety, Tolerability, and Immunogenicity of HEPTAVAX-II Manufactured Using a Modified Process.
Phase of Trial: Phase III
Latest Information Update: 18 Apr 2017
At a glance
- Drugs Hepatitis B vaccine recombinant (Primary)
- Indications Hepatitis B
- Focus Adverse reactions; Pharmacodynamics; Registrational
- Sponsors Merck & Co
- 01 Nov 2012 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
- 17 May 2012 Status changed from recruiting to active, no longer recruiting as reported by ClinicalTrials.gov.
- 29 Dec 2011 Status changed from not yet recruiting to recruiting as reported by ClinicalTrials.gov.